000 03089naaaa2200373uu 4500
001 https://directory.doabooks.org/handle/20.500.12854/53855
005 20220220081829.0
020 _a978-2-88919-720-0
020 _a9782889197200
024 7 _a10.3389/978-2-88919-720-0
_cdoi
041 0 _aEnglish
042 _adc
100 1 _aRoger Chung
_4auth
700 1 _aPaul A. Adlard
_4auth
245 1 0 _aThe molecular pathology of cognitive decline: Focus on metals
260 _bFrontiers Media SA
_c2016
300 _a1 electronic resource (175 p.)
506 0 _aOpen Access
_2star
_fUnrestricted online access
520 _aIn the past two decades there have been significant advances made in understanding the cellular and molecular alterations that occur with brain ageing, as well as with our understanding of age-related brain diseases. Ageing is associated with a mid-life decline in many cognitive domains (eg. Attention, working memory, episodic memory) that progresses with advancing age and which may be potentiated by a variety of diseases. However, despite the breadth of attempts to explain it, the underlying basis for age-related memory impairment remains poorly understood. Both normal and “pathological” ageing (as in age-related neurodegenerative disorders such as Alzheimer’s disease) may be associated with overlapping and increased levels of “abnormal” pathology, and this may be a potential mediator of cognitive decline in both populations. An emerging hypothesis in this field is that metal ion dys/homeostasis may represent a primary unifying mechanism to explain age- and disease-associated memory impairment – either indirectly via an effect on disease pathogenesis, or by a direct effect on signaling pathways relevant to learning and memory. There remains a concerted worldwide effort to deliver an effective therapeutic treatment for cognitive decline associated with ageing and/or disease, which is currently an unmet need. There have been numerous clinical trials conducted specifically testing drugs to prevent cognitive decline and progression to dementia, but to date the results have been less than impressive, highlighting the urgent need for a greater understanding of the neurobiological basis of memory impairment in ageing and disease which can then drive the search for effective therapeutics.
540 _aCreative Commons
_fhttps://creativecommons.org/licenses/by/4.0/
_2cc
_4https://creativecommons.org/licenses/by/4.0/
546 _aEnglish
653 _aDown Syndrome
653 _aAmyotrophic Lateral Sclerosis
653 _aParkinson's disease
653 _aaluminium
653 _aIron
653 _aTBI
653 _aCognition
653 _aCopper
653 _aAlzheimer's disease
653 _aZinc
856 4 0 _awww.oapen.org
_uhttp://journal.frontiersin.org/researchtopic/1341/the-molecular-pathology-of-cognitive-decline-focus-on-metals
_70
_zDOAB: download the publication
856 4 0 _awww.oapen.org
_uhttps://directory.doabooks.org/handle/20.500.12854/53855
_70
_zDOAB: description of the publication
999 _c75540
_d75540